


HCC CC E84.9 Cystic fibrosis, unspecified

DEFINITION Defective gene causing overproduction of mucous that builds up in lung passages, resulting in life-threatening respiratory problems.

Cystic fibrosis, unspecified**4 E85 Amyloidosis**

EXCLUDES 2 Alzheimer's disease (G30.0-)

HCC CC E85.0 Non-neuropathic hereditary amyloidosis

Hereditary amyloid nephropathy

Code also associated disorders, such as:
autoinflammatory syndromes (M04.-)

EXCLUDES 2 Transthyretin-related (ATTR) familial amyloid cardiomyopathy (E85.4)

HCC CC E85.1 Neuropathic hereditary amyloidosis

Amyloid polyneuropathy (Portuguese)

Transthyretin-related (ATTR) familial amyloid polyneuropathy

AHA: 4Q 2012, 99-100

HCC CC E85.2 Hereditary amyloidosis, unspecified**HCC CC E85.3 Secondary systemic amyloidosis**

Hemodialysis-associated amyloidosis

DEFINITION Secondary amyloidosis is also known as reactive systemic amyloidosis, in which the deposited protein fibrils are of the AA type caused by a reaction to a chronic infection or other condition, such as osteomyelitis, rheumatoid arthritis, or a noninfectious disease process such as kidney failure with long term hemodialysis.

HCC CC E85.4 Organ-limited amyloidosis

Localized amyloidosis

Transthyretin-related (ATTR) familial amyloid cardiomyopathy

5 E85.8 Other amyloidosis**HCC CC E85.81 Light chain (AL) amyloidosis**

AHA: 4Q 2017, 6; AHA: 2Q 2024, 8

HCC CC E85.82 Wild-type transthyretin-related (ATTR) amyloidosis

Senile systemic amyloidosis (SSA)

AHA: 4Q 2017, 6

HCC CC E85.89 Other amyloidosis

AHA: 4Q 2017, 6

HCC CC E85.9 Amyloidosis, unspecified

DEFINITION Abnormal accumulation of amyloid-like proteins in tissues.

4 E86 Volume depletion

Use additional code(s) for any associated disorders of electrolyte and acid-base balance (E87.-)

EXCLUDES 1 dehydration of newborn (P74.1)
postprocedural hypovolemic shock (T81.19)
traumatic hypovolemic shock (T79.4)

EXCLUDES 2 hypovolemic shock NOS (R57.1)

E86.0 Dehydration

GUIDELINES Section I.C.2.c.3)

When the admission/encounter is for management of dehydration due to the malignancy and only the dehydration is being treated (intravenous rehydration), the dehydration is sequenced first, followed by the code(s) for the malignancy.

AHA: 1Q 2014, 7; AHA: 2Q 2019, 6

E86.1 Hypovolemia

Depletion of volume of plasma

DEFINITION Abnormal decrease in the total volume of circulating blood with a corresponding loss of sodium electrolytes.

E86.9 Volume depletion, unspecified

AHA: 2Q 2019, 6

4 E87 Other disorders of fluid, electrolyte and acid-base balance

EXCLUDES 1 diabetes insipidus (E23.2)
electrolyte imbalance associated with hyperemesis gravidarum (O21.1)
electrolyte imbalance following ectopic or molar pregnancy (O08.5)
familial periodic paralysis (G72.3)
metabolic acidemia in newborn, unspecified (P19.9)

CC E87.0 Hyperosmolality and hyponatremia

Sodium [Na] excess

Sodium [Na] overload

EXCLUDES 2 diabetes with hyperosmolality (E08, E09, E11, E13 with final characters .00 or .01)

AHA: 1Q 2014, 7; AHA: 1Q 2022, 21

CC E87.1 Hypo-osmolality and hyponatremia

Sodium [Na] deficiency

EXCLUDES 1 syndrome of inappropriate secretion of antidiuretic hormone (E22.2)

AHA: 1Q 2014, 7

5 E87.2 Acidosis

EXCLUDES 1 diabetic acidosis - see categories E08-E10, E11, E13 with ketoacidosis

DEFINITION An abnormal increase in the acidity of body fluids, caused either by accumulation of acids or by depletion of bicarbonates.

AHA: 3Q 2020, 24; AHA: 4Q 2024, 13

CC E87.20 Acidosis, unspecified

Lactic acidosis NOS

Metabolic acidosis NOS

Code also:

, if applicable, respiratory failure with hypercapnia (J96, with 5th character 2)

AHA: 4Q 2022, 10

CC E87.21 Acute metabolic acidosis

Acute lactic acidosis

AHA: 4Q 2022, 10

CC E87.22 Chronic metabolic acidosis

Chronic lactic acidosis

Code first:

underlying etiology, if applicable

AHA: 4Q 2022, 10

CC E87.29 Other acidosis

Respiratory acidosis NOS

EXCLUDES 2 acute respiratory acidosis (J96.02)
chronic respiratory acidosis (J96.12)

AHA: 4Q 2022, 10

CC E87.3 Alkalosis

Alkalosis NOS

Metabolic alkalosis

Respiratory alkalosis

CC E87.4 Mixed disorder of acid-base balance**E87.5 Hyperkalemia**

Potassium [K] excess

Potassium [K] overload

DEFINITION An abnormally high concentration of potassium ions in the blood.

- E87.6 Hypokalemia**
Potassium [K] deficiency
DEFINITION Low potassium level in the blood causing neuromuscular disorders ranging from weakness to paralysis, electrocardiographic abnormalities, renal disease, and gastrointestinal disorders.
- E87.7 Fluid overload**
EXCLUDES 1 edema NOS (R60.9)
fluid retention (R60.9)
DEFINITION High infusion rates or transfusion volumes not processed effectively by the recipient, causing circulatory system overload marked by acute respiratory distress.
- E87.70 Fluid overload, unspecified**
AHA: 1Q 2023, 17
- E87.71 Transfusion associated circulatory overload**
Fluid overload due to transfusion (blood) (blood components)
TACO
- E87.79 Other fluid overload**
- E87.8 Other disorders of electrolyte and fluid balance, not elsewhere classified**
Electrolyte imbalance NOS
Hyperchloremia
Hypochloremia
- E88 Other and unspecified metabolic disorders**
Use additional codes for associated conditions
EXCLUDES 1 histiocytosis X (chronic) (C96.6)
- E88.0 Disorders of plasma-protein metabolism, not elsewhere classified**
EXCLUDES 1 monoclonal gammopathy (of undetermined significance) (D47.2)
polyclonal hypergammaglobulinemia (D89.0)
Waldenström macroglobulinemia (C88.00)
EXCLUDES 2 disorder of lipoprotein metabolism (E78.-)
- E88.01 Alpha-1-antitrypsin deficiency**
AAT deficiency
- E88.02 Plasminogen deficiency**
Dysplasminogenemia
Hypoplasminogenemia
Type 1 plasminogen deficiency
Type 2 plasminogen deficiency
Code also:
, if applicable, ligneous conjunctivitis (H10.51-)
Use additional code for associated findings, such as:
hydrocephalus (G91.4)
otitis media (H67.-)
respiratory disorder related to plasminogen deficiency (J99)
AHA: 4Q 2018, 6
- E88.09 Other disorders of plasma-protein metabolism, not elsewhere classified**
Bisalbuminemia
- E88.1 Lipodystrophy, not elsewhere classified**
EXCLUDES 1 Whipple's disease (K90.81)
DEFINITION Defective fat metabolism resulting in abnormal or degenerative subcutaneous fat deposits that appear as lumps or dents under the skin.
- E88.10 Lipodystrophy, unspecified**
Lipodystrophy NOS
- E88.11 Partial lipodystrophy**
Acquired partial lipodystrophy (APL)
Barraquer-Simons lipodystrophy
Familial partial lipodystrophy (FPLD)
- E88.12 Generalized lipodystrophy**
Acquired generalized lipodystrophy (AGL)
Berardinelli-Siepe syndrome
Congenital generalized lipodystrophy (CGL)
Lawrence syndrome

- E88.13 Localized lipodystrophy**
Injection lipodystrophy
Insulin lipodystrophy
- E88.14 HIV-associated lipodystrophy**
Code first:
any human immunodeficiency virus [HIV] disease (B20)
Use additional code for adverse effect, if applicable, to identify drug (T37.5X5-)
- E88.19 Other lipodystrophy, not elsewhere classified**
- E88.2 Lipomatosis, not elsewhere classified**
Lipomatosis NOS
Lipomatosis (Check) dolorosa [Dercum]
AHA: 1Q 2025, 19
- E88.3 Tumor lysis syndrome**
Tumor lysis syndrome (spontaneous)
Tumor lysis syndrome following antineoplastic drug chemotherapy
Use additional code for adverse effect, if applicable, to identify drug (T45.1X5)
AHA: 2Q 2019, 19; AHA: 1Q 2020, 30
- E88.4 Mitochondrial metabolism disorders**
EXCLUDES 1 disorders of pyruvate metabolism (E74.4)
Kearns-Sayre syndrome (H49.81)
Leber's disease (H47.22)
Leigh's encephalopathy (G31.82)
Mitochondrial myopathy, NEC (G71.3)
Reye's syndrome (G93.7)
- E88.40 Mitochondrial metabolism disorder, unspecified**
- E88.41 MELAS syndrome**
Mitochondrial myopathy, encephalopathy, lactic acidosis and stroke-like episodes
- E88.42 MERRF syndrome**
Myoclonic epilepsy associated with ragged-red fibers
Code also:
progressive myoclonic epilepsy (G40.3-)
- E88.43 Disorders of mitochondrial tRNA synthetases**
ARS2-related mitochondrial disorders
LBSL
Leukoencephalopathy with brainstem - spinal cord involvement - lactate elevation
Leukoencephalopathy with thalamus - brainstem involvement - high lactate
LTBL
Mitochondrial aminoacyl-tRNA synthetase disorders
Code also, if applicable, associated condition such as:
leukoencephalopathy (G93.49)
AHA: 4Q 2023, 10
- E88.49 Other mitochondrial metabolism disorders**
- E88.8 Other specified metabolic disorders**
- E88.81 Metabolic syndrome and other insulin resistance**
Use additional codes for associated manifestations, such as:
obesity (E66.-)
AHA: 3Q 2022, 6
- E88.810 Metabolic syndrome**
Dysmetabolic syndrome
CODING TIPS Metabolic syndrome (also called dysmetabolic syndrome X) involves a cluster of symptoms placing individuals at risk for development of a number of disease processes. Manifestations of metabolic syndrome confirmed by the provider, such as obesity (and BMI as calculated by the clinical record documentation), should additionally be coded following E88.810.
AHA: 4Q 2023, 11
- E88.811 Insulin resistance syndrome, Type A**
AHA: 4Q 2023, 11
- E88.818 Other insulin resistance**
Insulin resistance syndrome, Type B
AHA: 4Q 2023, 11
- E88.819 Insulin resistance, unspecified**
AHA: 4Q 2023, 11

● New **Manifestation** 4–7 Digit Indicators ☒ Laterality **A** Adult **M** Maternity **N** Newborn **P** Pediatrics
▲ Revised **Unspecified** AHA Coding Clinic

- E88.82 Obesity due to disruption of MC4R pathway**
Use additional code, if applicable, to identify associated manifestations, such as polyphagia (R63.2)
Use additional code to identify body mass index (BMI), if known (Z68.-)
AHA: 4Q 2024, 9

- HCC E88.89 Other specified metabolic disorders**
Launois-Bensaude adenolipomatosis
EXCLUDES 1 adult pulmonary Langerhans cell histiocytosis (J84.82)

E88.9 Metabolic disorder, unspecified

- E88.A Wasting disease (syndrome) due to underlying condition**
Cachexia due to underlying condition
Code first:
underlying condition
EXCLUDES 1 cachexia NOS (R64)
nutritional marasmus (E41)
EXCLUDES 2 failure to thrive (R62.51, R62.7)
AHA: 4Q 2023, 12

Postprocedural endocrine and metabolic complications and disorders, not elsewhere classified (E89)

CODING TIPS Postprocedural complications are coded to E89. These conditions should only be assigned when diagnostic statements clearly indicate that the condition is a complication of a procedure.

- 4 E89 Postprocedural endocrine and metabolic complications and disorders, not elsewhere classified**
EXCLUDES 2 intraoperative complications of endocrine system organ or structure (E36.0-, E36.1-, E36.8)
- E89.0 Postprocedural hypothyroidism**
Postirradiation hypothyroidism
Postsurgical hypothyroidism
DEFINITION Underactive thyroid gland due to surgery or radiation, causing an inadequate production of thyroid hormone and a slowing of metabolic processes.
- CC E89.1 Postprocedural hypoinsulinemia**
Postpancreatectomy hyperglycemia
Postsurgical hypoinsulinemia
Code first:
, if applicable, diabetes mellitus (postpancreatectomy) (postprocedural) (E13.-)
Use additional code, if applicable, to identify:
acquired absence of pancreas (Z90.41-)
insulin use (Z79.4)
EXCLUDES 1 transient postprocedural hyperglycemia (R73.9)
transient postprocedural hypoglycemia (E16.2)
GUIDELINES **Section I.C.4.a.6)(b)(i)**
For postpancreatectomy diabetes mellitus (lack of insulin due to the surgical removal of all or part of the pancreas), assign code E89.1, Postprocedural hypoinsulinemia. Assign a code from category E13 as the principal or first-listed diagnosis and a code from subcategory Z90.41, Acquired absence of pancreas, as an additional code.
CODING TIPS Because the pancreas is the organ that produces insulin, the removal of even a portion of the pancreas can produce diabetic-like symptoms. If manifestations are produced because of the hyperglycemia and lack of insulin, the provider must document support for adding the codes for manifestations after E89.1 with the appropriate E13 code(s). Also add the acquired absence of pancreas (Z90.41-) and use of insulin (Z79.4).
AHA: 1Q 2024, 3

- E89.2 Postprocedural hypoparathyroidism**
Parathyroprival tetany
AHA: 3Q 2023, 10

- E89.3 Postprocedural hypopituitarism**
Postirradiation hypopituitarism

- 5 E89.4 Postprocedural ovarian failure**
E89.40 Asymptomatic postprocedural ovarian failure
Postprocedural ovarian failure NOS
E89.41 Symptomatic postprocedural ovarian failure
Symptoms such as flushing, sleeplessness, headache, lack of concentration, associated with postprocedural menopause

- E89.5 Postprocedural testicular hypofunction**

- CC E89.6 Postprocedural adrenocortical (-medullary) hypofunction**

- 5 E89.8 Other postprocedural endocrine and metabolic complications and disorders**

- 6 E89.81 Postprocedural hemorrhage of an endocrine system organ or structure following a procedure**

- CC E89.810 Postprocedural hemorrhage of an endocrine system organ or structure following an endocrine system procedure**

- CC E89.811 Postprocedural hemorrhage of an endocrine system organ or structure following other procedure**

- 6 E89.82 Postprocedural hematoma and seroma of an endocrine system organ or structure**

- CC E89.820 Postprocedural hematoma of an endocrine system organ or structure following an endocrine system procedure**

- CC E89.821 Postprocedural hematoma of an endocrine system organ or structure following other procedure**

- CC E89.822 Postprocedural seroma of an endocrine system organ or structure following an endocrine system procedure**

- CC E89.823 Postprocedural seroma of an endocrine system organ or structure following other procedure**

- CC E89.89 Other postprocedural endocrine and metabolic complications and disorders**
Use additional code, if applicable, to further specify disorder